Contents
A review by four immunologists at St. Jude Children’s Research Hospital, published in Cell Research on Sept. 4, 2026, explains how innate immune sensors assemble into inflammasomes and PANoptosomes, the protein complexes that set off inflammation and inflammatory cell death. Its main conclusions are that cryo-electron microscopy has shown how several sensors switch from a resting to an active form, that most drug candidates so far target a single sensor, NLRP3, and that no complete structure of an assembled inflammasome or PANoptosome has yet been solved.
The researchers Saurabh Upadhyay, Raghavendra Nagampalli, Sara Resende along with Thirumala-Devi Kanneganti review existing studies instead of detailing a novel trial, and the publication is made available with open access.
What inflammasomes and PANoptosomes are
Inflammasomes are complexes that activate the enzyme caspase-1. Caspase-1 matures two inflammatory signaling molecules, IL-1β and IL-18, and cuts the protein gasdermin D, which opens pores in the cell membrane.
PANoptosomes drive PANoptosis, an inflammatory form of cell death that combines features of pyroptosis, apoptosis and necroptosis. Inflammasomes can be part of them, and they also release other signals such as TNF and interferons. The sensors the review places in PANoptosomes include ZBP1, AIM2, RIPK1, NLRP3, NLRP1, NLRC5 and NLRP12.
How the main sensors switch on
NLRP3 rests in a cage-like cluster until the protein NEK7 binds to it. It then reorganizes into a disk-shaped complex that grows filaments to recruit the adapter protein ASC. AIM2 switches on when it binds double-stranded DNA, which releases its self-inhibition.
| Sensor | What activates or restrains it | Conditions the review links to it |
|---|---|---|
| NLRP3 | Triggered following NEK7 binding | Cryopyrin-associated periodic syndromes (CAPS); Alzheimer’s and Parkinson’s disease |
| NLRP1 | Suppressed by DPP9 until a detached fragment builds filaments | Skin and autoimmune conditions; traumatic brain injury |
| NAIP/NLRC4 | NAIP recognizes bacterial molecules like flagellin to oligomerize NLRC4 | Enterocolitis caused by gain-of-function mutations |
| Pyrin | Its triggering relies on phosphorylation controlled by Rho GTPases alongside 14-3-3 proteins | Familial Mediterranean fever (FMF) |
The review also connects these pathways to infections, which they help fight and which pathogens try to suppress, and to obesity, diabetes, gout and cardiovascular and kidney disease. In cancer their role depends on the context, with studies reporting both tumor-promoting and tumor-suppressing effects.
The current state of pharmaceutical research
Most candidates target NLRP3. MCC950, the best-known inhibitor, holds the sensor in its inactive shape, but its clinical development has been limited by off-target toxicity and by its failure to block some CAPS-causing variants. Other NLRP3 agents include CY-09, dapansutrile (OLT1177) and molecules that degrade NEK7, and the review notes that some have reached clinical evaluation.
Further down the pathway, the review covers blocking caspase-1 and gasdermin D. For FMF, colchicine remains the most widely used treatment, although it does not act specifically on Pyrin. The authors suggest that targeting individual sensors, rather than shared parts such as ASC or caspase-1, could make treatments more precise, and they name IL-1β, IL-18, C-reactive protein and ferritin as possible markers of disease activity.
What remains unknown
To this day, an atomic-resolution structure for a completely assembled inflammasome or PANoptosome remains elusive, leaving many suggested PANoptosome models derived strictly from imaging, biochemical, and genetic insights. Both NLRC5 and NLRP12 are characterized solely at the individual domain level, while the complete architecture of Pyrin continues to be unknown. Furthermore, the majority of structural investigations have relied on a single trigger, failing to capture the physiological reality of the human body, where multiple signals frequently converge simultaneously.
References
- Upadhyay S., Nagampalli R., Resende S. and Kanneganti T.-D., “Innate immune sensors of inflammasomes and PANoptosomes: structural–mechanistic insights and therapeutic implications”, Cell Research, vol. 36, pp. 747–768, published Sept. 4, 2026. Open-access full text on PubMed Central.